ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI
Award amount
$671,659Program and phase
STTR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ASTROCYTE PHARMACEUTICALS INC.
- Proposal award date
- 2015-09-30
- Contract end date
- 2018-06-30
- UEI
- ZEP1G3FGYUP3
- Solicitation number
- PA14-072
- Topic code
- 105
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
- Preclinical development of AST-004 for astrocyte-mediated treatment of TBI.
- Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Multi-omic CSF Assay for the Diagnosis of Brain Cancers
- A unified eligibility application and determination system to increase Ryan White linkage to care and retention in care by reducing structural barriers and facilitating client engagement
- Novel carriers for enhanced oligonucleotide permeability through the blood-brain barrier
- PEP/PrEP via Pharmacist-Prescribing Implementation (PEPPI)
- Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery
Research funding history
4 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $5,465,311. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services